Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
CardioRenal receives FDA Breakthrough Device Designation for TENOR
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), […]
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
Inhibrx, a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare […]
Genprex Receives Approval to Advance Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Takeda and HUTCHMED have announced that the U.S. Food and Drug Administration (“FDA”) has granted […]
FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria
The U.S. Food and Drug Administration (FDA) has approved Xacduro (sulbactam for injection; durlobactam for […]
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
Vega Therapeutics, a clinical-stage biotechnology company developing novel therapies for rare blood disorders, today announced […]
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]
Antengene Announces Antibody-Drug Conjugate Granted Orphan Drug Designations by the FDA for the Treatment of Gastric and Pancreatic Cancers
Antengene Corporation, a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing […]
Food and Drug Administration (FDA) and Clarivate Extend Material Transfer Agreement for Three Additional Years
Clarivate, a global leader in connecting people and organizations to intelligence they can trust to […]
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Sangamo Therapeutics, a genomic medicine company, today announced that the United States Food and Drug […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more